The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce ...

Merck Animal Health is investing $895 million in a new De Soto facility, which will bring hundreds of jobs to the area. The ...

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case for receiving a grant to invest in their ambitious project. During the ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...

April 29 (Reuters) - U.S. drugmaker Merck (MRK.N), opens new tab said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D capabilities at the site.

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case for receiving a grant to invest in their ambitious project.